Articles

Clinical trial assessing the additive benefit of alpelisib to fulvestrant in treatment-refractory HR-positive/HER2-negative ABC currently enrolling patients. Read More ›

Results from the SOLAR-1 study demonstrate that only PIK3CA mutations can predict sensitivity to alpelisib in patients with HR-positive/HER2-negative breast cancer. Read More ›

Findings from Cohort A of the BYLieve study suggest that treatment of HR-positive/HER2-negative breast cancer with PIK3CA mutation drivers with alpelisib plus fulvestrant may lead to long-term disease control. Read More ›

Clinical trial assessing alpelisib plus tucatinib in HER2-positive mBC with PIK3CA mutations is currently enrolling patients. Read More ›

Interim analysis of the RIBANNA trial demonstrates that ribociclib provides a meaningful PFS benefit and maintains QOL in patients with HR-positive/HER2-negative advanced breast cancer. Read More ›


Comprehensive analysis of acquired resistance mutations in patients with HR-positive/HER2-negative advanced breast cancer post-CDK4/6 inhibitor and endocrine therapy is the largest to date. Read More ›

Results from the MONALEESA trials show that PFS benefit with ribociclib in combination with endocrine therapy found to be consistent regardless of expression levels of most cell cycle genes. Read More ›

Analysis from the MONALEESA and RIBANNA trials in patients with HR-positive/HER2-negative advanced breast cancer finds differences in PFS among patients treated with ribociclib in combination with endocrine therapy among MONALEESA-like subgroups. Read More ›

An overview of recently passed legislation and proposals anticipated in the coming year Read More ›

Page 22 of 147